Thu, February 22, 2018

Matthew Luchini Maintained (BLUE) at Buy with Increased Target to $222 on, Feb 22nd, 2018

Matthew Luchini of BMO Capital, Maintained "bluebird bio, Inc." (BLUE) at Buy with Increased Target from $215 to $222 on, Feb 22nd, 2018.

Matthew has made no other calls on BLUE in the last 4 months.



There are 9 other peers that have a rating on BLUE. Out of the 9 peers that are also analyzing BLUE, 5 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Michael Schmidt of "Leerink Swann" Downgraded from Buy to Hold on, Thursday, January 25th, 2018
  • Mark Breidenbach of "Oppenheimer" Initiated at Hold on, Thursday, December 21st, 2017
  • Jason McCarthy of "Maxim Group" Downgraded from Strong Buy to Hold on, Wednesday, December 13th, 2017
  • Josh Schimmer of "Evercore ISI Group" Downgraded from Buy to Hold on, Monday, November 6th, 2017
  • Matthew Harrison of "Morgan Stanley" Upgraded from Sell to Hold on, Friday, November 3rd, 2017


These are the ratings of the 4 analyists that currently disagree with Matthew


  • Biren Amin of "Jefferies" Upgraded from Hold to Strong Buy on, Monday, December 11th, 2017
  • John Newman of "Canaccord Genuity" Initiated at Strong Buy and Held Target at $202 on, Tuesday, December 5th, 2017
  • Dane Leone of "BTIG" Upgraded from Hold to Strong Buy on, Thursday, November 2nd, 2017
  • Gena Wang of "Barclays" Maintained at Buy with Increased Target to $162 on, Thursday, November 2nd, 2017